Keywords: Roche, Tarceva, EURTAC, NSCLC

Roche’ Tarceva nearly doubles progression-free survival vs chemotherapy

Article | 06 July 2011

Print This

In a trial dubbed EURTAC, the first Phase III study to include Western lung cancer patients first-line treatment with erlotinib, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in